Table 1.

More advanced active clinical trials using vitamin D as therapeutic agent for COVID-19.

Clinical Trial ID	Development Phase	Aim
NCT04536298	Phase 3	The work is carried out in patients recently diagnosed with Covid-19 and the goal lies in the intake of a nutritional supplement of vitamin D to evaluate an improvement in patients (reducing the rates of hospitalization and death). Likewise, this study states that the intake of vitamin D reduces the risk of infection with the SARS-CoV-2 virus.
NCT04385940	Phase 3	The objective of this three-week study in patients with Covid-19 is to determine the relationship between initial deficiency of vitamin D and the clinical characteristics of patients, with improvement of the clinical phenotype in patients with vitamin D supplement.
NCT04483635	Phase 3	This 16-week study aims to demonstrate that patients infected with SARS-CoV-2 who ingest a high-dose of vitamin D supplementation decrease their incidence of infection and the severity and duration of the disease.
NCT04535791	Phase 3	The aim of this study is to evaluate the efficacy of vitamin D supplementation against virus infection for Covid-19 healthcare workers.
NCT04411446	Phase 4	The objective is to determine whether an oral dose of vitamin D is able to prevent the occurrence of respiratory derangement and other adverse clinical events in Covid-19 hospitalized patients.
NCT04502667	Phase 3	This study tests the efficacy of vitamin D treatment in Covid-19 pediatric patients
NCT04344041	Phase 3	This study is examining whether high-dose vitamin D supplementation improves the prognosis of older patients diagnosed with COVID-19 compared to a standard dose of vitamin D.
NCT04386850	Phase 2–3	This clinical trial is evaluating the therapeutic efficacy of rapidly correcting vitamin D deficiency in adults to reduce the risk SARS-CoV-2 infection and the viral infection, and mitigate the morbidity and mortality associated with COVID-19.